Search Result

Results for "

C. difficile

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (13) ATP Synthase (1) Autophagy (1) Bacterial (25) CRFR (2) DNA/RNA Synthesis (5) Fungal (1) Gap Junction Protein (1) Isotope-Labeled Compounds (3) MDM-2/p53 (1) Reference Standards (3)
By Research Areas:	Cancer (1) Infection (28) Inflammation/Immunology (6) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0975

Penicillin V Potassium Phenoxymethylpenicillin potassium salt	Bacterial Antibiotic	Infection
Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-B0975A

Penicillin V Phenoxymethylpenicillin	Antibiotic Bacterial	Infection
Penicillin V (Phenoxymethylpenicillin) is a potent and orally active antibiotic. Penicillin V shows antibacterial activity for Streptococci, Clostridium difficile and staphylococcus aureus. Penicillin V has the potential for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-16753

Ridinilazole 1 Publications Verification SMT19969	Bacterial	Infection
Ridinilazole is a novel antibacterial with MICs range of 0.06-0.25 µg/mL (MIC₉₀=8 µg/mL) against C. difficile.

HY-P1137

10Panx 1 Publications Verification	Gap Junction Protein	Others
10Panx is a competitive inhibitor of selective Pannexin 1 (PANX1) channels. 10Panx blocks the opening of PANX1 channels, inhibits ATP release and downstream P2X7 receptor-mediated signaling pathways, thereby reducing cell death and inflammatory responses. 10Panx can be used in the study of diseases such as neuropathic pain, inflammatory bowel disease, and Clostridioides difficile infection. 10Panx can effectively reduce mechanical hyperalgesia and enhanced C-reflexes, and inhibit the expression of pro-inflammatory factors such as IL-6[1][2][3].

HY-128357

Ibezapolstat 4 Publications Verification ACX-362E; GLS-362E	Bacterial DNA/RNA Synthesis	Infection
Ibezapolstat (ACX-362E) is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a K_i of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat is developed for the research of C. difficile infection(CDI) .

HY-P9929

Bezlotoxumab 1 Publications Verification BLA761046; MBL-CDB1; MDX-1388	Bacterial	Infection
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .

HY-P1108

Astressin 2B 1 Publications Verification	CRFR	Neurological Disease Inflammation/Immunology
Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC₅₀=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .

HY-P1108A

Astressin 2B TFA 1 Publications Verification	CRFR	Neurological Disease Inflammation/Immunology
Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC₅₀=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .

HY-18324

CRS3123 1 Publications Verification REP-3123	Antibiotic	Inflammation/Immunology
CRS3123 is a potent and orally active narrow-spectrum antibiotic. CRS3123 inhibits bacterial methionyl-tRNA synthetase. CRS3123 has potent activity against Clostridium difficile (C. difficile) and aerobic Gram-positive bacteria but little activity against Gram-negative bacteria, including anaerobes. CRS3123 has the potential for the research of C. difficile infections .

HY-105099

Rifalazil KRM-1648; ABI-1648	Antibiotic DNA/RNA Synthesis Bacterial	Infection Inflammation/Immunology
Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase . Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml . Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB) .

HY-172670

Spore germination-IN-1	Fungal	Infection
Spore germination-IN-1 (Compound 110) is an orally active spore germination inhibitor (IC₅₀: 14 μM). Spore germination-IN-1 specifically inhibits the enzymatic activities of mature SleC and CspB on spores (K_d: 12 and 8 μM). Spore germination-IN-1 can be used in studies against C. difficile .

HY-148041

ATPase-IN-2	ATP Synthase	Others
ATPase-IN-2 is an ATPase inhibitor with an IC₅₀ value of 0.9 μM. ATPase-IN-2 inhibits C. difficile toxin B (TcdB) glycohydrolase activity with an AC₅₀ value of 30.91 μM. ATPase-IN-2 can be used for the research of ATP-related .

HY-156191

Cholic acid anilide	Bacterial	Infection
Cholic acid anilide, a Narylcholan-24-amide, is a potent inhibitor of C. difficile spore germination with an IC₅₀ value of 1.8 μM in the spore germination assay conducted in Sodium phosphate media containing 6 mM Taurocholate (HY-B1131) and 12 mM Glycine (HY-Y0966). Cholic acid anilide has the potential for C. difficile infections research .

HY-B0975S1

Penicillin V-d5 potassium Phenoxymethylpenicillin-d5 potassium salt	Bacterial Antibiotic	Infection
Penicillin V-d₅ (potassium) is the deuterium labeled Penicillin V Potassium . Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-B0975AR

Penicillin V (Standard) Phenoxymethylpenicillin (Standard)	Reference Standards Antibiotic Bacterial	Infection
Penicillin V (Standard) is the analytical standard of Penicillin V. This product is intended for research and analytical applications. Penicillin V (Phenoxymethylpenicillin) is a potent and orally active antibiotic. Penicillin V shows antibacterial activity for Streptococci, Clostridium difficile and staphylococcus aureus. Penicillin V has the potential for the research of otitis, sinusitis, pharyngitis and tonsillitis [4].

HY-156283

Antibacterial agent 159	Antibiotic	Infection
Antibacterial agent 159 (Compound 6d) is an antibiotic. Antibacterial agent 159 can effective against impetigo and C. difficile infection (CDI). Antibacterial agent 159 has no observed recurrence for C. difficile and exertes a minimal impact on the beneficial gut microbiome .

HY-B0975R

Penicillin V Potassium (Standard) Phenoxymethylpenicillin potassium salt (Standard)	Reference Standards Bacterial Antibiotic	Infection
Penicillin V (Potassium) (Standard) is the analytical standard of Penicillin V (Potassium). This product is intended for research and analytical applications. Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-163142

Antibacterial agent 172	Bacterial	Infection
Antibacterial agent 172 (Compound 6a) is a <,i>Clostridioides difficile (Cd) SpoVD inhibitor (IC₅₀=89 nM) that effectively inhibits sporulation of Clostridioides difficile. Antibacterial agent 172 can be used in the study of bacterial infections .

HY-128357A

Ibezapolstat hydrochloride ACX-362E hydrochloride; GLS-362E hydrochloride	Bacterial DNA/RNA Synthesis	Infection
Ibezapolstat hydrochloride is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a K_i of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat hydrochloride is developed for the research of C. difficile infection(CDI) .

HY-156282

Antibacterial agent 158	Bacterial	Infection
Antibacterial agent 158 (compound 6c), a Micrococcin analogue, and is effective against impetigo and C. difficile* infection* (CDI) .

HY-171005

VPC162134	Bacterial	Infection
VPC162134 is an antibacterial agent, that inhibits H. pylori, C. jejuni, MRSA and S. epidermidis with MIC of 2.9, 17.5, 93.3 and 93.3 μM. VPC162134 is an inhibitor for pyruvate ferredoxin oxidoreductase (PFOR) .

HY-123354

SC 44914	Bacterial	Infection
SC 44914 is a quinoxaline compound with antibacterial effects. SC-44914 has activity against Campylobacter jejuni, C. coli, and Clostridium difficile .

HY-172768

SCUT1-2	Bacterial	Infection
SCUT1-2 is a bifunctional antibacterial agent with good oral bioavailability in mice (F=56.8%). SCUT1-2 can kill the vegetative cells of C. difficile with a MIC of 0.06-0.50 μg/mL, and inhibit spore germination in vitro. SCUT1-2 could alleviate the symptoms of weight loss and diarrhea in mice caused by C. difficile infection (CDI) and prevent recurrent CDI .

HY-W749146

Raja 42	Antibiotic Bacterial	Infection
Raja 42 is a gamma lactam antibiotic. Raja 42 is effective against a variety of different bacterias, including Gram-positive and Gram-negative bacteria, such as C. difficile strains .

HY-B0975S

Penicillin V-13C6 potassium Phenoxymethylpenicillin-13C6 potassium salt	Isotope-Labeled Compounds Bacterial Antibiotic	Infection
Penicillin V- ¹³C₆ (potassium) is the ¹³C₆ labeled Penicillin V (potassium). Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis.

HY-163042

HSGN-218	Bacterial	Infection
HSGN-218 is an antibacterial agent with low Caco-2 permeability. HSGN-218 efficiently inhibits the growth of different C. difficile species with MIC values ranging from 0.007 μM to 0.07 μM.

HY-W750848

Raja 42-d10	Isotope-Labeled Compounds Bacterial Antibiotic	Infection
Raja 42-d₁₀ is the deuterium labeled Raja 42 (HY-W749146). Raja 42 is a gamma lactam antibiotic. Raja 42 is effective against a variety of different bacterias, including Gram-positive and Gram-negative bacteria, such as C. difficile strains .

HY-149610

Antibacterial agent 156	Bacterial	Infection
Antibacterial agent 156 (Compound 57) is a selective and potent bactericidal against C. difficile and targets cell-wall synthesis. Antibacterial agent 156 exhibits bactericidal activity with the minimal inhibitory concentration of 0.5 μg/mL and 1 μg/mL against MIMIC50 (101 strains) and MIC90 (101 strains) .

HY-B0975AS

Penicillin V-d5	Isotope-Labeled Compounds Bacterial Antibiotic	Infection
Penicillin V-d₅ (Phenoxymethylpenicillin-d₅) is the deuterium labeled Penicillin V. Penicillin V (Phenoxymethylpenicillin) is an orally active antibiotic. Penicillin V inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-105099R

Rifalazil (Standard) KRM-1648 (Standard); ABI-1648 (Standard)	Antibiotic Reference Standards DNA/RNA Synthesis Bacterial	Infection Inflammation/Immunology
Rifalazil (Standard) is the analytical standard of Rifalazil. This product is intended for research and analytical applications. Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase[1]. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml[3]. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB)[2].

HY-P10914

D-CopA3	MDM-2/p53 Autophagy	Inflammation/Immunology Cancer
D-CopA3 is the inhibitor for MDM2 and the activator for p53 signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC₅₀=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models .

HY-131476

NAI-802	Bacterial	Infection
NAI-802 is a new lantibiotic. NAI-802 can be produced by Actinoplanes sp. NAI-802 shows a significant activity against Gram-positive anaerobic bacteria, such as Clostridium difficile, C. butyricum, C. perfringens and Peptostreptococcus asaccharolyticus with MIC ranges of 0.25-2 μg/mL .

HY-116880

DS-2969b	Bacterial DNA/RNA Synthesis	Infection
DS-2969b is an orally active GyrB inhibitor with antibacterial activity. DS-2969b is is active against Clostridium difficile infection (MIC₉₀: 0.06 μg/mL), which is 2-, 16-, and 32-fold lower than those of Fidaxomicin (HY-17580), Metronidazole (HY-B0318), and Vancomycin (HY-B0671), respectively. DS-2969b inhibits the supercoiling activity of C. difficile DNA gyrase. DS-2969b also exhibits activity against other Gram-positive anaerobes, including strict and facultative anaerobes. DS-2969b is safe and well tolerated in preclinical toxicology studies .

Cat. No.	Product Name	Target	Research Area

HY-P1137

10Panx 1 Publications Verification	Gap Junction Protein	Others
10Panx is a competitive inhibitor of selective Pannexin 1 (PANX1) channels. 10Panx blocks the opening of PANX1 channels, inhibits ATP release and downstream P2X7 receptor-mediated signaling pathways, thereby reducing cell death and inflammatory responses. 10Panx can be used in the study of diseases such as neuropathic pain, inflammatory bowel disease, and Clostridioides difficile infection. 10Panx can effectively reduce mechanical hyperalgesia and enhanced C-reflexes, and inhibit the expression of pro-inflammatory factors such as IL-6[1][2][3].

HY-P1108

Astressin 2B 1 Publications Verification	CRFR	Neurological Disease Inflammation/Immunology
Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC₅₀=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .

HY-P1108A

Astressin 2B TFA 1 Publications Verification	CRFR	Neurological Disease Inflammation/Immunology
Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC₅₀=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .

HY-P10914

D-CopA3	MDM-2/p53 Autophagy	Inflammation/Immunology Cancer
D-CopA3 is the inhibitor for MDM2 and the activator for p53 signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC₅₀=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9929

Bezlotoxumab 1 Publications Verification BLA761046; MBL-CDB1; MDX-1388	Bacterial	Infection
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .

HY-P99277

Actoxumab Anti-C. difficile Toxin A Recombinant Antibody	Inhibitory Antibodies	Infection
Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB .

Penicillin V Potassium Phenoxymethylpenicillin potassium salt	Infection Microorganisms Anti-inflammation/Immunoregulatory Classification of Application Fields Antibiotics Antibacterial Disease Research Disease Research Fields Beta-lactam Antibiotics Source Classification	Bacterial Antibiotic
Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

Penicillin V Potassium (Standard) Phenoxymethylpenicillin potassium salt (Standard)	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Antibiotics Antibacterial Disease Research Beta-lactam Antibiotics Source Classification	Reference Standards Bacterial Antibiotic
Penicillin V (Potassium) (Standard) is the analytical standard of Penicillin V (Potassium). This product is intended for research and analytical applications. Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P79219

	*Toxin B/TcdB Protein, C. difficile* (His)** 2 Publications Verification Toxin B; Glucosyltransferase TcdB; toxB	Others	E. coli
	Toxin B/TcdB protein is the precursor of the cytotoxin TcdB, which can strategically destroy the colon epithelium and cause host inflammatory response and diarrhea in Clostridium difficile infection. Compared with TcdA, TcdB has higher virulence and is essential for eliciting host responses. Toxin B/TcdB Protein, C. difficile (His) is the recombinant Toxin B/TcdB protein, expressed by E. coli , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0975S1

Penicillin V-d5 potassium
Penicillin V-d₅ (potassium) is the deuterium labeled Penicillin V Potassium . Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

HY-B0975S

Penicillin V-13C6 potassium
Penicillin V- ¹³C₆ (potassium) is the ¹³C₆ labeled Penicillin V (potassium). Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally active antibiotic. Penicillin V Potassium inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V Potassium can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis.

HY-W750848

Raja 42-d10
Raja 42-d₁₀ is the deuterium labeled Raja 42 (HY-W749146). Raja 42 is a gamma lactam antibiotic. Raja 42 is effective against a variety of different bacterias, including Gram-positive and Gram-negative bacteria, such as C. difficile strains .

HY-B0975AS

Penicillin V-d5
Penicillin V-d₅ (Phenoxymethylpenicillin-d₅) is the deuterium labeled Penicillin V. Penicillin V (Phenoxymethylpenicillin) is an orally active antibiotic. Penicillin V inhibits the growth of Streptococci, C. difficile and S. aureus. Penicillin V can be used for the research of otitis, sinusitis, pharyngitis and tonsillitis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

C. difficile

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products